164 related articles for article (PubMed ID: 35849723)
1. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study.
Tun AM; Khurana A; Mwangi R; Link BK; Wang Y; Feldman AL; Thompson CA; Novak AJ; Villasboas JC; Thanarajasingam G; Farooq U; Syrbu S; Nowakowski GS; Witzig TE; Ansell SM; Rimsza LM; Cerhan JR; Habermann TM; Maurer MJ
Blood Adv; 2022 Sep; 6(17):5210-5221. PubMed ID: 35849723
[TBL] [Abstract][Full Text] [Related]
2. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
Williams ME; Hong F; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ; Kahl BS
Br J Haematol; 2016 Jun; 173(6):867-75. PubMed ID: 26970533
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.
Nie G; Sun L; Zhang C; Yuan Y; Mao H; Wang Z; Li J; Duan S; Xing C; Zhang B
Front Immunol; 2022; 13():903315. PubMed ID: 36172352
[TBL] [Abstract][Full Text] [Related]
6. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
Hester LL; Park SI; Wood WA; Stürmer T; Brookhart MA; Lund JL
Cancer; 2019 Apr; 125(7):1101-1112. PubMed ID: 30548238
[TBL] [Abstract][Full Text] [Related]
7. Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Poddubnaya IV; Alekseev SM; Kaplanov KD; Lukavetskyy LM; Rekhtman GB; Dolai TK; Attili VSS; Bermúdez CD; Isaev AA; Chernyaeva EV; Ivanov RA
Hematol Oncol; 2020 Feb; 38(1):67-73. PubMed ID: 31724191
[TBL] [Abstract][Full Text] [Related]
8. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
9. Research progress on epigenetics of small B-cell lymphoma.
Ruan X; Zhang R; Zhu H; Ye C; Wang Z; Dong E; Li R; Cheng Z; Peng H
Clin Transl Oncol; 2022 Aug; 24(8):1501-1514. PubMed ID: 35334078
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.
Patel N; Durkin L; Bodo J; Hsi ED
Am J Clin Pathol; 2020 Apr; 153(5):646-655. PubMed ID: 31953940
[TBL] [Abstract][Full Text] [Related]
12. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
13. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma of the ocular adnexa: A study of 353 cases.
Ferry JA; Fung CY; Zukerberg L; Lucarelli MJ; Hasserjian RP; Preffer FI; Harris NL
Am J Surg Pathol; 2007 Feb; 31(2):170-84. PubMed ID: 17255761
[TBL] [Abstract][Full Text] [Related]
15. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
16. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
17. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
